WILMINGTON, Del., Jan. 15,
2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc.
(Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a
clinical-stage biopharmaceutical company, and HOPE Therapeutics,
Inc., a development stage medical and technology driven company and
wholly owned subsidiary of NRx, today announced the appointment of
Mr. Michael Taylor and Ms.
Anita Nunes as Member and Observer
of its Board of Directors, respectively. Ms. Nunes is also to
be appointed to the Board of Directors of Hope Therapeutics,
Inc.
Michael Taylor brings over 25
years of experience in global credit markets, with a focus on
special situations and capital formation. He has served as Partner
at the Adi Dassler International Family Office in Nassau, Bahamas, and as Managing Director at
Oppenheimer & Co., where he specialized in complex debt
structuring and multijurisdictional transactions. Prior to that, he
spent eight years at Stone & Youngberg as Managing Director of
Institutional Fixed Income Trading and Alternative Investments.
Michael began his career as a Bond Trader at Morgan Stanley.
A graduate of the London School of
Economics with a Bachelor of Science in Economics and
International Relations, Michael has built a reputation for
navigating complex financial environments and delivering innovative
solutions. These skills will be integral to the growth of the HOPE
clinic network. He joins NRx Pharmaceuticals as the Board
Designee of Smith & Sauer, LLC, following the recently
announced financing.
Anita Nunes, CEO and Co-Founder
of Smith & Sauer, LLC, is an accomplished executive with more
than 20 years of experience leading transformative growth across
industries. She has driven investments in pioneering ventures,
including Smith and Sauer's recent $27
million investment in Hope Therapeutics and NRx
Pharmaceuticals, where her leadership is advancing mental health
care and pharmaceutical innovation.
Anita has a strong background in artificial intelligence, where
she has led global initiatives to integrate AI-driven solutions,
enabling businesses to achieve operational excellence and adapt to
dynamic market demands. Her extensive healthcare expertise includes
work with industry leaders McKesson and Gilead, where she was
instrumental in managing strategic initiatives and fostering
innovation.
In addition to her work at Smith & Sauer, Anita is the
Founder of Mocktail Nation, a health-conscious beverage brand, and
Pluzze Consulting, where she has provided strategic guidance to
empower entrepreneurs and investors. Her ability to align financial
strategies with impactful outcomes has positioned her as a leader
in purpose-driven investments, delivering long-term value to
stakeholders and society. She has served on multiple Boards of
Directors and is recognized for her extensive expertise in
healthcare, technology, and pharmaceuticals.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx plans to file an NDA for Accelerated Approval for
NRX-101 in patients with bipolar depression and suicidality or
akathisia. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced initiation of filing a New Drug
Application for NRX-100 (IV ketamine) for the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under a data sharing agreement. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
development stage healthcare delivery company that intends to
develop a best-in-class network of interventional psychiatry
clinics to offer ketamine transcranial magnetics stimulation (TMS)
and other lifesaving therapies to patients with suicidal depression
and related disorders, together with a digital therapeutic-enabled
platform designed to augment and preserve the clinical benefit of
NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as
"may," "will," "should," "would," "expect," "plan," "believe,"
"intend," "look forward," and other similar expressions among
others. These statements relate to future events or to the
Company's future financial performance, and involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from any future
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects the Company's current views with respect to
future events and is subject to these and other risks,
uncertainties and assumptions relating to the Company's operations,
results of operations, growth strategy, liquidity, Hope
Therapeutic's ability to consummate the acquisitions of providers
for its national network, the Company's ability to raise adequate
capital to fund the Hope Therapeutics acquisitions, and the
Company's ability to spin-off Hope Therapeutics. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's most recent Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission. Investors and security
holders are urged to read these documents free of charge on the
SEC's website at http://www.sec.gov. Except as may be required
by applicable law, The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, whether
as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE
Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-the-appointment-of-michael-taylor-to-its-board-of-directors-and-appointment-of-anita-nunes-as-board-observer-ms-nunes-to-be-appointed-director-of-hope-therapeutics-inc-302351477.html
SOURCE NRx Pharmaceuticals, Inc.
